Table 1 Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazone

 Placebo Group Troglitazone group P

n 122 144

Clinical characteristics

 Age (years) 34.3 ± 6.5 34.9 ± 6.6 0.52

 BMI (kg/m2) 30.3 ± 5.3 30.6 ± 6.1 0.63

 Waist-to-hip circumference ratio 0.86±0.05 0.85 ± 0.06 0.19

 Using hormonal contraceptives \* 48% 43% 0.41

OGTT ƚ

 Fasting Glucose (mg/dl) 98.1 ± 9.1 98.7 ± 10.2 0.64

2-h glucose 154.0 ± 24.0 154.4 ± 27.0 0.97

 Total glucose area 18.7 ± 2.0 18.9 ± 2.0 0.25

 (mg/dl x min x 10-3) ï

 Impaired glucose tolerance© 72% 69% 0.66

 Fasting Insulin (µU/ml) 16.0 ± 7.5 17.0 ± 10.8 0.82

 Total insulin area (µU/ml x min) ï 10,209 ± 5536 9,902 ± 6543 0.55